Chemistry:Cannabidiphorol
Cannabidiphorol, the heptyl-homologue of cannabidiol was identified as a natural phytocannabinoid and named cannabidiphorol (CBDP) in 2019.[1] It had previously been reported as a synthetic compound,[2] but was not identified as a natural product prior to 2019. Recently, CBDP has been gained popularity due to it being synthesized and available on a commercial level.[3]
Pharmacology
Pharmacodynamics
CBDP shows weak antagonism at both cannabinoid receptors (CB1 and CB2), similar to cannabidiol (CBD). CBD, however, exhibits stronger antagonism at CB2, reaching a 33% maximum response of SR144528 versus CBDP's 23%.[4]
Both cannabinoids act as weak agonists at the serotonin 5-HT1A receptor, contributing to potential anxiolytic effects.[4]
Unlike CBD, CBDP shows no sign of dopamine D2 receptor agonism.[4]
Unexpectedly, CBDP acts as a positive allosteric modulator (PAM) at the MOR, enhancing met-enkephalin signaling by 37%, potentially affecting pain perception.[4]
References
- ↑ "A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol". Scientific Reports 9 (1): 20335. December 2019. doi:10.1038/s41598-019-56785-1. PMID 31889124. Bibcode: 2019NatSR...920335C.
- ↑ Makriyannis A, Nikas SP, Alapafuja SO, "Angiogenic resorcinol derivatives", US patent Abandoned 2012/172339, published 5 July 2012.
- ↑ "What Is CBDP? Everything You Need To Know" (in en). 27 May 2024. https://herb.co/learn/what-is-cbdp-everything-you-need-to-know.
- ↑ 4.0 4.1 4.2 4.3 "CBD Versus CBDP: Comparing In Vitro Receptor-Binding Activities". International Journal of Molecular Sciences 25 (14): 7724. July 2024. doi:10.3390/ijms25147724. PMID 39062976.
See also
 |  |
